Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)
CUSIP: 90400D108
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 98,367,418
- Total 13F shares
- 94,131,376
- Share change
- +5,240,549
- Total reported value
- $3,423,160,510
- Put/Call ratio
- 63%
- Price per share
- $36.36
- Number of holders
- 307
- Value change
- +$191,188,547
- Number of buys
- 167
- Number of sells
- 150
Quarterly Holders Quick Answers
What is CUSIP 90400D108?
CUSIP 90400D108 identifies RARE - Ultragenyx Pharmaceutical Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 90400D108:
Top shareholders of RARE - Ultragenyx Pharmaceutical Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
10%
|
9,996,226
|
$361,963,343 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.1%
from 13D/G
|
6,158,266
|
$222,990,812 | — | 31 Mar 2025 | |
| SANDS CAPITAL MANAGEMENT, LLC |
13D/G
13F
|
Company |
4.7%
|
4,298,003
|
$163,238,154 | $0 | 31 Dec 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
3.3%
|
3,218,942
|
$116,559,000 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.7%
|
2,618,490
|
$94,815,523 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
|
Company |
2.7%
|
2,457,543
|
$93,337,483 | $0 | 31 Dec 2024 | |
| Clearbridge Investments, LLC |
13F
|
Company |
2.3%
|
2,259,705
|
$81,823,922 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.2%
|
2,149,000
|
$77,815,290 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
2.1%
|
2,055,200
|
$74,418,792 | — | 31 Mar 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
2,024,500
|
$73,307,145 | — | 31 Mar 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
1.7%
|
1,707,402
|
$61,825,026 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.7%
|
1,701,493
|
$61,611,061 | — | 31 Mar 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.7%
|
1,685,729
|
$61,040,248 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
1,646,537
|
$59,640,121 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.6%
|
1,576,114
|
$57,071,088 | — | 31 Mar 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
1.5%
|
1,495,351
|
$54,146,660 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.4%
|
1,409,199
|
$51,957,478 | — | 31 Mar 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
1.4%
|
1,394,434
|
$50,492,455 | — | 31 Mar 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
1.4%
|
1,350,000
|
$48,883,500 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.3%
|
1,247,380
|
$45,167,630 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
1.2%
|
1,213,282
|
$43,932,940 | — | 31 Mar 2025 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
1.2%
|
1,150,456
|
$41,658,000 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.99%
|
976,052
|
$35,342,848 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.95%
|
937,200
|
$33,936,012 | — | 31 Mar 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.87%
|
852,657
|
$30,874,710 | — | 31 Mar 2025 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
0.84%
|
830,000
|
$30,054,300 | — | 31 Mar 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.84%
|
824,418
|
$29,852,174 | — | 31 Mar 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.74%
|
728,017
|
$26,361,496 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.72%
|
712,393
|
$25,795,751 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.71%
|
696,161
|
$25,207,999 | — | 31 Mar 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.67%
|
658,715
|
$23,852,070 | — | 31 Mar 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.66%
|
651,383
|
$23,586,578 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.64%
|
633,152
|
$22,926,434 | — | 31 Mar 2025 | |
| First Light Asset Management, LLC |
13F
|
Company |
0.64%
|
632,033
|
$22,885,915 | — | 31 Mar 2025 | |
| Eagle Health Investments LP |
13F
|
Company |
0.64%
|
627,600
|
$22,725,396 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.64%
|
626,400
|
$22,681,967 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.61%
|
600,446
|
$21,742,149 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.6%
|
593,121
|
$21,476,911 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.58%
|
568,389
|
$20,581,367 | — | 31 Mar 2025 | |
| LOOMIS SAYLES & CO L P |
13F
|
Company |
0.57%
|
561,479
|
$20,331,000 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.57%
|
556,417
|
$20,147,860 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.54%
|
527,980
|
$19,118,156 | — | 31 Mar 2025 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
0.53%
|
524,637
|
$18,997,106 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.53%
|
518,543
|
$18,776,441 | — | 31 Mar 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
0.52%
|
516,228
|
$18,692,616 | — | 31 Mar 2025 | |
| GW&K Investment Management, LLC |
13F
|
Company |
0.51%
|
502,211
|
$18,185,000 | — | 31 Mar 2025 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
|
Company |
0.51%
|
502,023
|
$18,178,253 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
0.51%
|
500,000
|
$18,105,000 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.49%
|
480,269
|
$17,390,577 | — | 31 Mar 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.49%
|
478,904
|
$17,341,114 | — | 31 Mar 2025 |
Institutional Holders of Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) as of Q2 2025
As of 30 Jun 2025,
Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) was held by
307 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
94,131,376 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., SANDS CAPITAL MANAGEMENT, LLC, JPMORGAN CHASE & CO, PRICE T ROWE ASSOCIATES INC /MD/, BAKER BROS. ADVISORS LP, FMR LLC, STATE STREET CORP, SUVRETTA CAPITAL MANAGEMENT, LLC, and Clearbridge Investments, LLC.
This page lists
308
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
297
Q2 2025 holders
307
Holder diff
10
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.